Epigenetic phenomena linked to diabetic complications

Nature Reviews Endocrinology

Volumn 6, Issue 12, 2010, Pages 665-675

  Pirola, Luciano ^a   Balcerczyk, Aneta ^a   Okabe, Jun ^a   El Osta, Assam ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLIPIZIDE; HISTONE; INSULIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE;

CHROMATIN STRUCTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC RETINOPATHY; DIET; DISEASE PREDISPOSITION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENE REPRESSION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL; REVIEW; VASCULAR DISEASE;

ANIMALS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPIGENESIS, GENETIC; HUMANS; HYPERGLYCEMIA; MODELS, BIOLOGICAL;

EID: 78649449258     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.188     Document Type: Review

References (87)

1. Sheetz, M. J. & King, G. L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288, 2579-2588 (2002).
2. McCarthy, M. I. & Froguel, P. Genetic approaches to the molecular understanding of type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 283, E217-E225 (2002).
3. Nesto, R. W. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am. J. Cardiovasc. Drugs 5, 379-387 (2005).
4. Mourad, J. J. & Le Jeune, S. Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J. Hypertens. 26 (Suppl. 3), S7-S13 (2008).
5. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001).
6. Forbes, J. M., Fukami, K. & Cooper, M. E. Diabetic nephropathy: where hemodynamics meets metabolism. Exp. Clin. Endocrinol. Diabetes 115, 69-84 (2007).
7. [No authors listed] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329, 977-986 (1993).
8. [No authors listed] UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 34, 877-890 (1991).
9. Writing team for the Diabetes Control and Complications Trial/Epidemiology Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290, 2159-2167 (2003).
10. Nathan, D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643-2653 (2005).
11. Nathan, D. M. et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch. Intern. Med. 169, 1307-1316 (2009).
12. Albers, J. W. et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 33, 1090-1096 (2010).
13. [No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853 (1998).
14. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
15. Chalmers, J. & Cooper, M. E. UKPDS and the legacy effect. N. Engl. J. Med. 359, 1618-1620 (2008).
16. Marshall, S. M. & Flyvbjerg, A. Prevention and early detection of vascular complications of diabetes. BMJ 333, 475-480 (2006).
17. Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008).
18. Gerstein, H. C. et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
19. Wong, T. Y. et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based crosssectional studies. Lancet 371, 736-743 (2008).
20. Writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287, 2563-2569 (2002).
21. Ling, C. & Groop, L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58, 2718-2725 (2009).
22. Lyssenko, V. et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N. Engl. J. Med. 359, 2220-2232 (2008).
23. van Hoek, M. et al. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 57, 3122-3128 (2008).
24. El-Osta, A. et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205, 2409-2417 (2008).
25. Engerman, R. L. & Kern, T. S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36, 808-812 (1987).
26. Kowluru, R. A. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 52, 818-823 (2003).
27. Hammes, H. P. et al. Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat. Invest. Ophthalmol. Vis. Sci. 34, 2092-2096 (1993).
28. Brasacchio, D. et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with geneactivating epigenetic marks that coexist on the lysine tail. Diabetes 58, 1229-1236 (2009).
29. Roy, S., Sala, R., Cagliero, E. & Lorenzi, M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc. Natl Acad. Sci. USA 87, 404-408 (1990).
30. Ihnat, M. A. et al. Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling. Diabetologia 50, 1523-1531 (2007).
31. Corgnali, M., Piconi, L., Ihnat, M. & Ceriello, A. Evaluation of gliclazide ability to attenuate the hyperglycaemic 'memory' induced by high glucose in isolated human endothelial cells. Diabetes Metab. Res. Rev. 24, 301-309 (2008).
32. Ceriello, A., Ihnat, M. A. & Thorpe, J. E. Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J. Clin. Endocrinol. Metab. 94, 410-415 (2009).
33. El-Osta, A. DNMT cooperativity-the developing links between methylation, chromatin structure and cancer. Bioessays 25, 1071-1084 (2003).
34. Ruthenburg, A. J., Allis, C. D. & Wysocka, J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol. Cell 25, 15-30 (2007).
35. Turner, B. M. Cellular memory and the histone code. Cell 111, 285-291 (2002).
36. Feng, Q. et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol. 12, 1052-1058 (2002).
37. Wang, H. et al. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol. Cell 8, 1207-1217 (2001).
38. Nishioka, K. et al. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 16, 479-489 (2002).
39. Li, Y. et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-κB-dependent inflammatory genes. Relevance to diabetes and inflammation. J. Biol. Chem. 283, 26771-26781 (2008).
40. Deering, T. G., Ogihara, T., Trace, A. P., Maier, B. & Mirmira, R. G. Methyltransferase Set7/9 maintains transcription and euchromatin structure at islet-enriched genes. Diabetes 58, 185-193 (2009).
41. Villeneuve, L. M. et al. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc. Natl Acad. Sci. USA 105, 9047-9052 (2008).
42. Kurash, J. K. et al. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol. Cell 29, 392-400 (2008).
43. Ea, C. K. & Baltimore, D. Regulation of NF-κB activity through lysine monomethylation of p65. Proc. Natl Acad. Sci. USA 106, 18972-18977 (2009).
44. Estève, P. O. et al. Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proc. Natl Acad. Sci. USA 106, 5076-5081 (2009).
45. Pradhan, S., Chin, H. G., Estève, P. O. & Jacobsen, S. E. SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics 4, 383-387 (2009).
46. Miao, F., Li, S., Chavez, V., Lanting, L. & Natarajan, R. Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17. Mol. Endocrinol. 20, 1562-1573 (2006).
47. Wang, J. et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41, 125-129 (2009).
48. Hotamisligil, G. S. & Spiegelman, B. M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 43, 1271-1278 (1994).
49. Nishikawa, T. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-790 (2000).
50. Miao, F., Gonzalo, I. G., Lanting, L. & Natarajan, R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J. Biol. Chem. 279, 18091-18097 (2004).
51. Xiang, K. et al. Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes 53, 228-234 (2004).
52. van Tilburg, J. H. et al. A genome-wide scan in type 2 diabetes mellitus provides independent replication of a susceptibility locus on 18p11 and suggests the existence of novel loci on 2q12 and 19q13. J. Clin. Endocrinol. Metab. 88, 2223-2230 (2003).
53. Gray, S. G. & De Meyts, P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab. Res. Rev. 21, 416-433 (2005).
54. Garber, K. Purchase of Aton spotlights HDAC inhibitors. Nat. Biotechnol. 22, 364-365 (2004).
55. Guarente, L. Sirtuins as potential targets for metabolic syndrome. Nature 444, 868-874 (2006).
56. Miao, F. et al. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J. Biol. Chem. 282, 13854-13863 (2007).
57. Nowak, S. J. & Corces, V. G. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 20, 214-220 (2004).
58. Weake, V. M. & Workman, J. L. Histone ubiquitination: triggering gene activity. Mol. Cell 29, 653-663 (2008).
59. Shiio, Y. & Eisenman, R. N. Histone sumoylation is associated with transcriptional repression. Proc. Natl Acad. Sci. USA 100, 13225-13230 (2003).
60. Ouyang, J. & Gill, G. SUMO engages multiple corepressors to regulate chromatin structure and transcription. Epigenetics 4, 440-444 (2009).
61. Smith, B. C. & Denu, J. M. Chemical mechanisms of histone lysine and arginine modifications. Biochim. Biophys. Acta 1789, 45-57 (2009).
62. An, W. Histone acetylation and methylation: combinatorial players for transcriptional regulation. Subcell. Biochem. 41, 351-369 (2007).
63. Imhof, A. et al. Acetylation of general transcription factors by histone acetyltransferases. Curr. Biol. 7, 689-692 (1997).
64. Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32-42 (2009).
65. Krause, B., Sobrevia, L. & Casanello, P. Epigenetics: new concepts of old phenomena in vascular physiology. Curr. Vasc. Pharmacol. 7, 513-520 (2009).
66. Chen, S. et al. Transcriptional coactivator p300 regulates glucose induced gene expression in the endothelial cells. Am. J. Physiol. Endocrinol. Metab. 298, E127-E137 (2010).
67. Kabra, D. G., Gupta, J. & Tikoo, K. Insulin induced alteration in post-translational modifications of histone H3 under a hyperglycemic condition in L6 skeletal muscle myoblasts. Biochim. Biophys. Acta 1792, 574-583 (2009).
68. Mosley, A. L. & Ozcan, S. Glucose regulates insulin gene transcription by hyperacetylation of histone h4. J. Biol. Chem. 278, 19660-19666 (2003).
69. Mosley, A. L., Corbett, J. A. & Ozcan, S. Glucose regulation of insulin gene expression requires the recruitment of p300 by the beta-cell-specific transcription factor Pdx-1. Mol. Endocrinol. 18, 2279-2290 (2004).
70. Mosley, A. L. & Ozcan, S. The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose. J. Biol. Chem. 279, 54241-54247 (2004).
71. El-Assaad, W. et al. Glucolipotoxicity alters lipid partitioning and causes mitochondrial dysfunction, cholesterol, and ceramide deposition and reactive oxygen species production in INS832/13 ss-cells. Endocrinology 151, 3061-3073 (2010).
72. Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315-322 (2009).
73. Liu, L., Li, Y. & Tollefsbol, T. O. Gene-environment interactions and epigenetic basis of human diseases. Curr. Issues Mol. Biol. 10, 25-36 (2008).
74. Reik, W., Dean, W. & Walter, J. Epigenetic reprogramming in mammalian development. Science 293, 1089-1093 (2001).
75. Maier, S. & Olek, A. Diabetes: a candidate disease for efficient DNA methylation profiling. J. Nutr. 132 (Suppl.), 2440S-2443S (2002).
76. Poirier, L. A. et al. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy. Metabolism 50, 1014-1018 (2001).
77. Thompson, R. F. et al. Experimental intrauterine growth restriction induces alterations in DNA methylation and gene expression in pancreatic islets of rats. J. Biol. Chem. 285, 15111-15118 (2010).
78. Einstein, F. et al. Cytosine methylation dysregulation in neonates following intrauterine growth restriction. PLoS ONE 5, e8887 (2010).
79. Orlando, V. & Paro, R. Mapping Polycombrepressed domains in the bithorax complex using in vivo formaldehyde cross-linked chromatin. Cell 75, 1187-1198 (1993).
80. Sekinger, E. A., Moqtaderi, Z. & Struhl, K. Intrinsic histone-DNA interactions and low nucleosome density are important for preferential accessibility of promoter regions in yeast. Mol. Cell 18, 735-748 (2005).
81. Schones, D. E. & Zhao, K. Genome-wide approaches to studying chromatin modifications. Nat. Rev. Genet. 9, 179-191 (2008).
82. Ceriello, A., Esposito, K., Ihnat, M., Thorpe, J. & Giugliano, D. Long-term glycemic control nfluences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes. J. Clin. Endocrinol. Metab. 94, 2751-2756 (2009).
83. Park, P. J. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev. Genet. 10, 669-680 (2009).
84. Lindström, J. et al. Take action to prevent diabetes-the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm. Metab. Res. 42 (Suppl. 1), S37-S55 (2010).
85. Paulweber, B. et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm. Metab. Res. 42 (Suppl. 1), S3-S36 (2010).
86. Schwarz, P E., Schwarz, J., Schuppenies, A., Bornstein, S. R. & Schulze, J. Development of a diabetes prevention management program for clinical practice. Public Health Rep. 122, 258-263 (2007).
87. Rothe, U. et al. Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care research. Diabetes Care 31, 863-868 (2008).